Prosecution Insights
Last updated: April 19, 2026

Dentons Cohen & Grigsby P.C.

28 pending office actions • 12 clients

Portfolio Summary

28
Total Pending OAs
13
Final Rejections
15
Non-Final OAs

Client Portfolio (12 clients)

Client (Assignee)Pending OAs
Actinium Pharmaceuticals, Inc. 7
Actinium Pharmaceuticals, Inc. 4
Revealit Corporation 3
Noveome Biotherapeutics, Inc. 3
First Insight, Inc. 1
Roesler Ip GmbH 1
Carnegie Mellon University 1
Signature Diagnostics Inc. 1
Spinnanker GmbH 1
Second Look, Inc. 1
Noveome Biotherapeutics, Inc. 1
Candice Hovell 1

Pending Office Actions

App #TitleClientExaminerArt UnitStatusFiled
19325478 SEMANTICALLY GENERATED VIDEO METHOD AND SYSTEM Revealit Corporation KY, KEVIN 2671 Final Rejection Sep 10, 2025
19325482 Semantically Interpreted Video Method, System, and Apparatus Revealit Corporation KY, KEVIN 2671 Final Rejection Sep 10, 2025
19224794 NEURAL NETWORK TRAINING FOR VIDEO GENERATION Revealit Corporation KY, KEVIN 2671 Final Rejection May 31, 2025
18904649 METHOD OF COLLECTING CONSUMER FEEDBACK IN THE METAVERSE First Insight, Inc. PUJOLS-CRUZ, MARJORIE 3624 Non-Final OA Oct 02, 2024
18883446 RESILIENT EXPANDABLE STERILIZABLE PACKAGING FOR INDIVIDUAL ITEMS Roesler Ip GmbH BUI, LUAN KIM 3736 Non-Final OA Sep 12, 2024
18838315 LIQUID CRYSTAL ELASTOMER WITH INTEGRATED SOFT THERMOELECTRICS FOR SHAPE MEMORY ACTUATION AND ENERGY HARVESTING Carnegie Mellon University KANG, TAE-SIK 1728 Non-Final OA Aug 14, 2024
18672909 IMPORTATION AND TRANSFORMATION TOOL FOR UTILIZING COMPUTER-AIDED DESIGN FILES IN A WEB BROWSER OR CUSTOMIZED CLIENT INTERFACE Unknown NGUYEN, ANH TUAN V 2619 Non-Final OA May 23, 2024
18662467 VEHICLE WASH SYSTEM Unknown ADHLAKHA, RITA P 1711 Non-Final OA May 13, 2024
18632379 HUMANIZED ANTI-CD45 ANTIBODIES Actinium Pharmaceuticals, Inc. CHASE, CAROL ANN 1646 Final Rejection Apr 11, 2024
18406715 LUGGAGE COVER Unknown WEAVER, SUE A 3733 Non-Final OA Jan 08, 2024
18514319 RELATIONAL BIOMARKERS THAT DISTINGUISH DISEASES AND DISORDERS FROM CONTROLS AND USES THEREOF TO PREDICT PATHOPHYSIOLOGICAL OUTCOMES Signature Diagnostics Inc. VANNI, GEORGE STEVEN 1686 Final Rejection Nov 20, 2023
18382028 ANCHORING PLATE Spinnanker GmbH HIJAZ, OMAR F 3635 Final Rejection Oct 19, 2023
18374875 METHOD FOR IDENTIFYING AND INITIATING REVERSIBLE SUBROGATION CLAIMS Second Look, Inc. KANAAN, TONY P 3696 Non-Final OA Sep 29, 2023
18036815 SECRETOME FRACTIONS AND USES THEREOF Noveome Biotherapeutics, Inc. KNIGHT, TERESA E 1634 Non-Final OA May 12, 2023
18025849 TROPHOBLAST GLYCOPROTEIN RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS Actinium Pharmaceuticals, Inc. CRAIG, KAILA ANGELIQUE 1618 Non-Final OA Mar 10, 2023
18146149 HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS Actinium Pharmaceuticals, Inc. LOCKARD, JON MCCLELLAND 1647 Non-Final OA Dec 23, 2022
17662474 Bioreactors and Bioreactor Facilities that Include a Plurality of Bioreactor Tiles Candice Hovell ABEL, LENORA A 1799 Final Rejection May 09, 2022
17726296 COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER Actinium Pharmaceuticals, Inc. ROGERS, JAMES WILLIAM 1618 Final Rejection Apr 21, 2022
17702648 COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER Actinium Pharmaceuticals, Inc. CUNNINGCHEN, KATHLEEN MARY 1646 Non-Final OA Mar 23, 2022
17532919 HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS Actinium Pharmaceuticals, Inc. LOCKARD, JON MCCLELLAND 1647 Non-Final OA Nov 22, 2021
17606254 COMPOSITIONS AND METHODS OF IMMUNODEPLETION FOR THE TREATMENT OF MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISEASES Actinium Pharmaceuticals, Inc. JONES, DAMERON LEVEST 1618 Final Rejection Oct 25, 2021
17494690 MODULATING ISCHEMIC INJURY Noveome Biotherapeutics, Inc. CLARKE, TRENT R 1651 Final Rejection Oct 05, 2021
17197580 Use of ST266 to Treat Severe Systemic Inflammation and Post-Acute COVID-19 Syndrome Noveome Biotherapeutics, Inc. FORD, VANESSA L 1674 Final Rejection Mar 10, 2021
16954105 COMBINATION IMMUNOTHERAPY AND CHEMOTHERAPY FOR THE TREATMENT OF A HEMATOLOGICAL MALIGNANCY Actinium Pharmaceuticals, Inc. WELLS, LAUREN QUINLAN 1622 Non-Final OA Jun 15, 2020
16755589 COMBINATION THERAPY FOR TREATMENT OF A HEMATOLOGICAL DISEASE Actinium Pharmaceuticals, Inc. BUTTICE, AUDREY L 1647 Final Rejection Apr 12, 2020
16755590 ANTI-CD45-BASED LYMPHODEPLETION METHODS AND USES THEREOF IN CONJUNCTION WITH ACT-BASED CANCER THERAPIES Actinium Pharmaceuticals, Inc. JOHANSEN, PETER N. 1644 Final Rejection Apr 12, 2020
16627872 TREATMENTS FOR A HEMATOLOGICAL MALIGNANCY Actinium Pharmaceuticals, Inc. SAMALA, JAGADISHWAR RAO 1618 Non-Final OA Dec 31, 2019
16690197 Novel methods for delivering therapeutics agents to the eye via the nasal passages Noveome Biotherapeutics, Inc. MOSS, NATALIE M 1653 Non-Final OA Nov 21, 2019

Managing Dentons Cohen & Grigsby P.C.'s Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month